PYC Therapeutics Ltd
ASX:PYC
PYC Therapeutics Ltd
Total Current Assets
PYC Therapeutics Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Current Assets
AU$153.7m
|
CAGR 3-Years
81%
|
CAGR 5-Years
22%
|
CAGR 10-Years
32%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Current Assets
$204.4m
|
CAGR 3-Years
43%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Total Current Assets
$11.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Current Assets
AU$15m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Current Assets
AU$261.4m
|
CAGR 3-Years
19%
|
CAGR 5-Years
27%
|
CAGR 10-Years
37%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Current Assets
AU$330.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
Glance View
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
See Also
What is PYC Therapeutics Ltd's Total Current Assets?
Total Current Assets
153.7m
AUD
Based on the financial report for Dec 31, 2025, PYC Therapeutics Ltd's Total Current Assets amounts to 153.7m AUD.
What is PYC Therapeutics Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
32%
Over the last year, the Total Current Assets growth was 147%. The average annual Total Current Assets growth rates for PYC Therapeutics Ltd have been 81% over the past three years , 22% over the past five years , and 32% over the past ten years .
